EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
The primary objective of the study is to assess the safety of nonconforming ide-cel.
University of Colorado Hospital
Peter Forsberg, MD
Protocol Number: 21-5082
More information available at ClinicalTrials.gov: NCT04771078
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers